Figure 3From: Increased levels of soluble CD226 in sera accompanied by decreased membrane CD226 expression on peripheral blood mononuclear cells from cancer patientsEffect of protease inhibitors on sCD226 level and mCD226 expression of normal PBMS or Jurkat cells. (A) Reduced levels of sCD226 in supernatant of PMA-stimulated PBMC or Jurkat cells treated with or without 1 mM protease inhibitor (1–10-Phenanathroline, AEBSF, or N-Ethylmaleimide). The data were the mean ± SD of three wells for each group. (*, P < 0.05 vs. nil group). (B) Enhanced expression of mCD226 on PMA-stimulated PBMC or Jurkat cells treated with or without 1 mM 1–10-Phenanathroline, AEBSF, or N-Ethylmaleimide. Solid line, without protease inhibitors; grey areas, with protease inhibitors; black areas, isotype controls. Representative experiments are shown (n = 3).Back to article page